Abstract
A novel series of fused tetrathiocines were prepared for evaluation of activity against the nucleocapsid protein of the feline immunodeficiency virus (FIV) in an in vitro cell culture approach. The results demonstrated that the compounds display potent nanomolar activity and low toxicity against this key model of HIV infection.
Highlights
A novel series of fused tetrathiocines were prepared for evaluation of activity against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) in an in-vitro cell culture approach
The results demonstrated that the compounds display potent nanomolar activity and low toxicity against this key model of HIV infection
Our longer-term objective is the development of a highly active, non-toxic drug candidate against the nucleocapsid protein, which would represent a major breakthrough in the treatment of HIV in humans and feline immunodeficiency virus (FIV) in cats
Summary
A novel series of fused tetrathiocines were prepared for evaluation of activity against the nucleocapsid protein of the feline immunodeficiency virus (FIV) in an in vitro cell culture approach. Published at: Asquith, Christopher R M; Meli, Marina L; Konstantinova, Lidia S; Laitinen, Tuomo; Poso, Antti; Rakitin, Oleg A; Hofmann-Lehmann, Regina; Allenspach, Karin; Hilton, Stephen T (2015).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call